Cenix BioScience and ugichem sign research agreement on development of novel gene silencing technology.
Cenix BioScience GmbH and ugichem GmbH announced that they have entered into a research agreement to advance the latter’s technology platform.
Under the agreed work plan, Cenix will apply its long-standing expertise in combining gene silencing analyses with high content screening in cultured cells. Cenix will adapt and implement multi-parametric microscopy-based assays using the Definiens XD image analysis system, to facilitate characterization and optimization of ugichem’s so-called Ugimer lead compounds.
“We are excited to launch this new relationship with ugichem and look forward to helping them advance their development programs,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “As we have successfully done for over a decade now, we expect that our specialist expertise and capabilities in this area will uniquely accelerate this innovative technology’s maturation”.
“We highly welcome Cenix’ expert know-how,” said Dr. Holger Bock, CEO of ugichem. “This project will strengthen the establishment and validation of our proprietary Ugimer chemistry, to further develop and expand what we think is the only new and promising chemistry approach to RNA therapeutics”.
Other news from the department business & finance
